Search results
...NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation COVID...
NewMediaWire via Yahoo Finance· 5 days ago10,000-participant randomized Phase 2b study will evaluate and compare GeoVax's multi-antigen, ...
3 No-Brainer Stocks to Buy for Under $100 Right Now
The Motley Fool via AOL· 20 hours agoEven if that target proves overly optimistic, much of the negative impact of the patent cliff could be offset by these new products and indications. Pfizer built a massive ...
Column: This GOP-leaning political polling firm has turned into a purveyor of anti-vaccine...
LA Times via Yahoo News· 4 days agoBlaming the COVID vaccines for a tide of undocumented injuries and deaths is a popular theme in the...
Marcum Wealth LLC Buys 3,926 Shares of Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 19 hours agoMarcum Wealth LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 11.8% during the first quarter, according to the company in its most recent filing ...
Gateway - Quartz
Quartz· 4 days agoThe company announced on Oct. 20 that it intends to sell the covid vaccine, marketed under the brand name Comirnaty, for $110 to $130 per dose. According ...
Apella Capital LLC Trims Stock Position in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 20 hours agoApella Capital LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 3.0% during the 1st quarter, according to its most recent 13F filing with the ...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 3 days agoThe company noted that it achieved 48% market share for Covid vaccines in the U.S. during the fall...
Feds try to delay release of non-public COVID vaccine safety data until at least 2026
Just the News· 3 days agoThe Biden administration is seeking to delay until at least 2026 the release of COVID-19 vaccine...
3 No-Brainer Stocks to Buy for Under $100 Right Now | The Motley Fool
The Motley Fool· 20 hours agoHere's why they picked AstraZeneca (AZN 0.41%), Bristol Myers Squibb (BMY 2.17%), and Pfizer (PFE)....
Vaccine Effectiveness against SARS-CoV-2 among Household Contacts during Omicron BA.2–Dominant...
Centers for Disease Control and Prevention· 5 days agoVaccine Effectiveness among Household Contacts
